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Epithelial cells, ﬁbroblasts and smooth muscle cells together form and give structure to the airway wall. These three tissue forming
cell types are structure giving elements and participate in the immune response to inhaled particles including allergens and dust.
All three cell types actively contribute to the pathogenesis of chronic inﬂammatory lung diseases such as asthma and chronic
obstructive pulmonary disease (COPD). Tissue forming cells respond directly to allergens through activated immunoglobulins
which then bind to their corresponding cell surface receptors. It was only recently reported that allergens and particles traﬃc
through epithelial cells without modiﬁcation and bind to the immunoglobulin receptors on the surface of sub-epithelial
mesenchymal cells. In consequence, these cells secrete pro-inﬂammatory cytokines, thereby extending the local inﬂammation.
Furthermore, activation of the immunoglobulin receptors can induce proliferation and tissue remodeling of the tissue forming
cells. New studies using anti-IgE antibody therapy indicate that the inhibition of immunoglobulins reduces the response of
tissue forming cells. The unmeasured questions are: (i) why do tissue forming cells express immunoglobulin receptors and (ii)
do tissue forming cells process immunoglobulin receptor bound particles? The focus of this review is to provide an overview of
the expression and function of various immunoglobulin receptors.
1.ChronicInﬂammatoryLungDiseases
The most prominent chronic inﬂammatory diseases of the
lung are asthma and chronic obstructive pulmonary disease
(COPD). These two common diseases are a major burden
for public health and aﬀect over 500 million people world-
wide (World Health Organization: WHO/NMH/CHP/CPM/
05.4.). Other chronic inﬂammatory lung diseases are hyper-
sensitivity pneumonitis which is caused by antigen exposure
and lung ﬁbrosis, the cause of which is unknown and there-
fore the pathology is widely uncertain [1–7]. To an unknown
reason the prevalence of all chronic inﬂammatory lung dis-
eases is on the rise especially in Asia [8, 9].
In Europe and the USA cigarette-smoke-induced COPD
was death cause no. 4 in 2008 and with a further increasing
prevalence it is expected to become death cause no. 3 within
the next decade. COPD is characterized by chronic inﬂam-
mation of the small airways, with similar pathologies
known for asthma [10–12]. These include airway constric-
tion, hyperplasia, and hypertrophy of mesenchymal cells,
increased mucus production, tissue remodeling, and ﬁnally
tissuedegradation,emphysema[10,11].Thelatterpathology
is regarded as a diﬀerent disease by some investigators [10].
Asthma is the most frequent chronic lung inﬂammation
inchildrenandisthemajorcauseofabsencefromschooland
work. Several studies indicated that the prevalence of asthma
isincreasing,especiallyincountrieswithanincreasingurban
life style [9, 13–15]. However, beside extensive investigations
worldwide the link of urban lifestyle and asthma is not
understood.Somestudiessuggestthatcountrysidelivingand
contact with animals of the mother during pregnancy and in
early childhood may be protective [16, 17]. Therefore these
studies indicate a central role of the innate immunity as well
as of the adaptive immunity [18, 19].
However, the molecular or cell biological events that lead
to the similar pathogenesis of chronic inﬂammatory lung
diseases in distinct segments of the lung are not fully under-
stood. Worse, there are no curative drugs available and only
the symptoms can be controlled. Asthma symptoms can be
reduced by inhaled glucocorticoids, long-acting β2-agonists,2 Journal of Allergy
muscarinicreceptorantagonists,orbyleukotrieneinhibitors,
phosphodiesterase inhibitors, or anti-IgE antibodies [20–
24]. Even there are an increasing number of drug classes
beingapprovedforasthmatherapyfromwhichallreducethe
inﬂammation, but do not show any eﬀect on the extensive
airway remodeling which is well documented in childhood
asthma [25–27].
In COPD there are not many therapeutic options besides
inhaled glucocorticoid and long-acting β2-agonists, and
their eﬃcacy is low in most patients [12, 28]. The fact that
remodeling of the airways persists after the environmental
stimulus is gone, while inﬂammation depends on the pres-
ence of a stimulus, points out that the immune response may
not always be the initiating factor for chronic inﬂammatory
lung diseases [29, 30].
Thecurrenthypothesisisthatchronicinﬂammatorylung
diseases are causatively linked to an overreactive or out of
control immune response to environmental factors [30, 31].
Asthma and other chronic inﬂammatory lung diseases can
be induced by nonallergic factors such as cold air, humidity,
exercise, or psychological stress [32–35]. Of course the
immune system plays a major role in the pathogenesis of
chronic inﬂammatory lung diseases, but there is evidence
that it may not be the initiating factor.
New investigations in primates and humans suggest
two major events that predispose an individual to develop
chronic inﬂammatory lung diseases during life: (i) maternal
exposure to environmental factors that reorganize the lungs
maturation during pregnancy and (ii) exposure to such
factors in the ﬁrst six years of life [29–31, 36–40]. The
mechanism how maternal behavior or exposure to risk
factors modiﬁes the embryonic lung development may
involve innate immunity or immunoglobulin synthesis [41,
42]. Interestingly one of the earliest signs of the lung’s
increased susceptibility to develop a chronic inﬂammatory
diseaseistheremodelingofthelargeorsmallairways[25,36,
37]. Unfortunately, we do not understand the mechanisms
how environmental factors increase the susceptibility of
the lung to develop chronic inﬂammation upon a second,
independent (unknown) triggering event. Neither do we
understand the disease speciﬁc mechanism(s) that leads to
the wide range of clinical phenotypes, nor for the diﬀerent
age of onset, nor the gender speciﬁcity [43–45]. In the
past two decades we accumulated knowledge of the immune
response in chronic inﬂammatory lung diseases, but this
knowledge did not help us to explain the entire pathology
of asthma or COPD or of any other chronic inﬂammatory
lung disease.
2 .T h eI m m u n eR e s po n s eo f
Tissue-Forming Cells
Tissue-forming cells have been excluded from studies of the
immuneresponseforalongtimeasitwasassumedthatthese
cell types do only respond to immunoglobulin indirectly
through cytokines and growth factors which are released
by activated immune cells after antigen or immunoglobulin
binding. However, there is evidence that this is not the full
story. Evidence for an active participation of tissue-forming
cell in the lungs response to allergens is provided by a
handful of research groups and thus the literature is rare.
In allergic asthma and some forms of COPD the immune
response is a central mechanism that initiates the pathology;
however, we do not fully understand how it works. The
immune response is a major cause of exacerbation in allergic
asthma, but it cannot explain how nonallergic asthma is
caused [32, 44, 46]. Asthma exacerbation can be induced by
exercise, stress, humidity, cold or hot air [19, 46]. However,
the immune response of the lung seems to be more complex
than anticipated for the past decades. Besides immune cells
the tissue-forming cells of the lung express immunoglobulin
receptors and respond to immunoglobulins.
To understand the cause of chronic inﬂammatory lung
diseases one has to include the contribution or the causative
role of tissue-forming resident cell types which give the lung
its structure and guarantee its function. In 1922 asthma was
ﬁrst described as a disease caused by overreactive airway
smooth muscle cells and an increased size and number
of smooth muscle bundles surrounding the airways [47].
Then the role of the immune cells and their response
to environmental factors were regarded as being more
important; however, recent studies refocused on the role of
the smooth muscle and its interaction with other cell types
[36, 48–52]. In COPD the disrupted interaction of epithelial
cells with the submucosal ﬁbroblasts has moved into the
centre of attention in the past years [36, 53–56]. However, to
identify the pathologic mechanism(s) that leads to chronic
inﬂammatory lung diseases one has to understand the
concertedinteractionofallcelltypeswitheachotherandthis
includes tissue-forming cells and immune cells (Figure 1).
One important aspect of allergic chronic inﬂammation
is the response of the lung to inhaled allergens. Therefore it
is surprising that the fact that tissue-forming cells include
bronchial epithelial cells, ﬁbroblasts, and airway smooth
muscle cells has drawn not much attention, while the
response of immune cells was such much in the focus
during the past decades. First reports on immunoglobulin
receptor expression and function in tissue-forming resident
lung cells were published in the 1980s, but did not trigger
extended investigations. In the following I will summarize
the knowledge of immunoglobulin receptor expression on
tissue-forming cells of the human lung and their possible
contribution to the pathogenesis of mainly asthma and
COPD.
3.EpithelialCells
Epithelial cells of the airway form the barrier between the
tissue and the inhaled air. They are the ﬁrst cell type which
is exposed to inhaled allergens, dust particles, vapor or
chemicals. The epithelial cell layer consists of two subtypes,
the outer ones are ciliated cells which are considered as end-
diﬀerentiated cells and which are shed oﬀ when they do
not function properly [57, 58]. The outer ciliated epithelial
cells are followed by a layer of basal epithelial cells, which




















Figure 1: The network of interactions between tissue-forming resident airway cells and immune cells.
or ciliated epithelial cells [53, 58–60]. The basal epithelial
cell layer is followed by the basement membrane which
consists of pure extracellular matrix (ECM). It was assumed
that the basal membrane forms an uninterrupted barrier
between epithelial cells and subepithelial ﬁbroblasts [45,
57]. However this view is challenged by several reports
that indicate direct cell-cell contacts between epithelial cells
and subepithelial ﬁbroblasts [61–64]. If such direct cell-
cell interactions between epithelial cells and submucosal
ﬁbroblasts exist, they must bridge the basal membrane and
this may act as a direct passage of inhaled substances into the
airway wall [65–68].
In asthma the number of columnar epithelial cells is
shed oﬀ more frequently and the number of goblet cells
is increased [59, 60]. Shedding may explain the reported
increased epithelial cell fragility; however, to increase shed-
ding additional factors must weaken the intercellular attach-
ment of neighboring epithelial cells and the basal epithelial
cells [57,58,61].InCOPDthedirectepithelialcell-ﬁbroblast
interaction seems to be disrupted [36, 53–56]. It is also
indicatedthatanabnormalexpressionoractivityofadhesion
molecules coupled with an alteration in the composition
of the extracellular matrix (ECM) in asthma and COPD
changes the response of the tissue-forming cells to antigens
and Ig receptors [65, 67, 68].
Epithelial cells respond to inhaled particles and allergens
not only through immune cell released cytokines, but also
through cell membrane receptors [69–72].Human bronchial
epithelial cells express the low-aﬃnity IgE receptor (CD23)
as well as the high-aﬃnity receptor and responded to
its activation [73, 74]. The activation of the low-aﬃnity
IgE receptor resulted in secretion of endothelin-1, a well-
known stimulator for ﬁbrotic processes [74], and the acti-
vation of the high-aﬃnity IgE receptor led to the release
of 15-hydroxyeicosatetraenoic acid from epithelial cells of
asthma patients only [73]. However, since this report by
Campbell et al. no other study investigated the role and
functionofthelow-aﬃnityIgEreceptoronepithelialcells.In
epithelial cells of the intestine of allergic patients it had been
shown that an allergen-IgE complex activated IL-8 secretion
via the intracellular signal proteins Erk1/2 mitogen-activated
protein kinase (MAPK) [75].
In an animal model it was suggested that allergen
inhalation upregulates the expression of the polymeric Ig
receptor by bronchial epithelial cells and its stimulation
increased IgM and IgA secretion [76]. The study showed
that this eﬀect was paralleled by Th17 cell activation, but
did not provide direct evidence for such a link. If such a
mechanism could be conﬁrmed in humans it would add
signiﬁcant weight to the regulation of immune response by
tissue-forming cells.
In vitro experiments in a rat model suggest that alveolar
epithelial cells also are able to express the IgG receptor
and its expression is aﬀected by glucocorticoids [77]. In
other species and epithelial cells of other organs than the
lung it had also been reported that the IgG receptors are
expressed and are functional[78,79]. Importantly itwasalso
shown that the predisposition to allergies can be mediated
by breastfeeding through maternal IgG and its receptor
expressiononembryoniclungepithelialcells[80].Onestudy
performed in rat epithelial cell monolayers suggested that
IgG via the Fc receptor enables antigen to be transferred
through the epithelium or the epithelial cell, respectively,
unchanged and be secreted on the apical side to subepithelial
mesenchymal cells [77]. This would be an important new
mechanism which will change the thinking of allergen
presentation and immune response in the lung if it could be
proven in an animal model or in humans.
Together these observations may be helpful to under-
stand particle traﬃcking through the epithelium barrier in
the lung and the contact of submucosal mesenchymal cells














Figure 2:Epithelial cells express IgEand IgGreceptors and respond
directlytotherespectiveimmunoglobulins.Suggested(dashedline)
and proven intracellular signaling pathways in human and animal
airway epithelial cells. Importantly the IgG receptor expressed on
airway epithelial cells may enable antigens to path un-changed
through the epithelium and then contact with subepithelial mes-
enchymal cells [77].
functions of immunoglobulin receptors on epithelial cells
are summarized in Figure 2. Unfortunately no studies have
conﬁrmed these data in humans.
4. AirwayFibroblasts and Fibrocytes
Bronchial submucosal ﬁbroblasts have been also reported to
be involved in the response to environmental factors and
to viral infection. The innate immune system was activated
by rhinovirus infection in humans and induced interferon-g
synthesis. Furthermore, it was shown that the virus repro-
duced in submucosal human bronchial ﬁbroblasts [83]. In
an ovalbumin inducible airway inﬂammation mouse model
it was reported that submucosal ﬁbrogenesis was induced by
the allergen through a Smad3-dependent pathway; however
the precise mechanism how the allergen activated the ﬁbrob-
last type cells was not characterized [84]. Another study
indicated that the increased submucosal airway remodeling
upon allergen stimulation involves the recomposition of the
ECM and is directed by the communication of epithelial cells
and submucosal ﬁbroblasts [85].
While no study reported the expression and function
of any immunoglobulin receptor on lung ﬁbroblasts there
is indirect evidence that this cell type must express such
receptors. Knight et al. reported in 1999 that IgE as well
as IL-1β stimulation increased leukemia inhibitory factor
(LIF) and its receptor (LIFR) in human lung tissue, with the
highest expression in ﬁbroblasts [86]. However, since these
experiments were performed in isolated tissue sections it
might be that the response of the ﬁbroblasts involved their
activation by mast cells.
Fibrocytes that were diﬀerentiated from CD14+ blood
cells and exposure to serum amyloid P, which bound to
the IgG receptor inhibited the signalling leading to ﬁbrocyte
diﬀerentiation. Furthermore, monoclonal antibodies bind-
ing to IgG receptor I (CD64) or II (CD32) also inhibit
ﬁbrocyte diﬀerentiation, indicating that tissue structure can
be directly modiﬁed by immunoglobulins [87].
5. AirwaySmooth MuscleCells
Bronchial or airway smooth muscle cells belong to the best
studied tissue-forming resident cells in asthma and COPD.
As mentioned above asthma was ﬁrst be considered as a
disease of the airway smooth muscle [47]. Most if not all
asthma patients show a signiﬁcant increase of airway smooth
muscle bundles and cell numbers within the bundles [25,
36, 50]. Investigations in childhood asthma and a more
recent asthma model in rhesus monkeys suggest that tissue
remodeling occurs already during pregnancy and is further
increased during the ﬁrst 6 years of life: mostly before any
sign of inﬂammation can be found [25, 36, 50, 88–92]. Other
studies even suggest that the exposure to environmental
factorsduringpregnancystartsamechanismthatderegulates
the lung maturation and predisposes the embryo to develop
chronic inﬂammatory lung diseases later in life [26, 36–
41, 92, 93].
In regard to COPD the exposure to cigarette smoke
seems to be an essential trigger; however, what sets the
lung to develop a chronic inﬂammation as a response to
allergic asthma stimuli is not known [39, 40, 44, 94, 95]. In
asthma models in rhesus monkeys the signiﬁcant structural
change of the airway smooth muscle cell bundles around
the airways of house dust mite and ozone-challenged animal
is impressive [92]. This observation is that in asthma the
smooth muscle cell bundles arrange in a spiral-like structure
which constricts the airways much more forcefully than the
randomly arranged muscle bundles in a healthy airway [92].
This leads back to some questions from the late Professor A.
Woolcock (Sydney University Royal Prince Alfred Hospital,
Sydney,Australia)toherstudents.Whatisthefunctionofthe
smooth muscle bundles in the normal lung? Why do we need
smooth muscle bundles around the airways? These questions
have never been answered.
Amongthenewclassesofasthmatherapiesareantibodies
that bind to IgE and neutralize it [24]. Anti-IgE antibodies
bind to the IgE receptor docking site and thus prevent
binding of IgE to its receptors. Recent studies indicate that
this new class of asthma drugs seems to be very eﬀective in
asthma therapy and signiﬁcantly reduces symptoms and the
need of other medications [96, 97]. It would be too easy to
argue that the beneﬁcial eﬀect of the anti-IgE antibodies is
achieved by the disruption of the IgE-IgE receptor interac-
tion of immune cells.
There are several studies starting from the late 1990s
that provide evidence that the airway smooth muscle cell
expresses and responds to the low as well as to the high IgE
aﬃnity receptors [98–103]. Furthermore, there is evidence
that the expression of the IgE receptors is increased in
asthma[102,103].InhibitionofIgEsigniﬁcantlyreducedthe
secretion of proinﬂammatory cytokines by airway smooth













Figure 3: Expression and function of immunoglobulins and their
receptors on human airway smooth muscle cells. Likely interaction
and crosstalk of Ig receptors through shared intracellular signaling
pathways. Reported pathways by which Ig receptors modulate
cytokine synthesis by tissue-forming cells in chronic inﬂammatory
lung diseases.
in vitro [104–106]. Furthermore, it has recently been shown
that IgE activates the transcription and expression of the
thymic stromal lymphopoietin in human airway smooth
muscle cells, a factor which is important to the recruitment
of circulating inﬂammatory cells into the lung [107]. This
ﬁnding supports the idea that the tissue-forming cells of the
airway wall signiﬁcantly contribute to the immune response
and that they may be the ﬁrst cells in the line of defense,
which are; however, deregulated in chronic inﬂammatory
lung diseases.
In response to IgE stimulation airway smooth muscle
cells have been shown to secrete proinﬂammatory cytokines
including IL-8, and eotaxin, which will attract neutrophils
and granulocytes to inﬁltrate the airway wall and thereby
extend the local inﬂammation [99, 101, 108]. These obser-
vations are in line with clinical studies showing an anti-
inﬂammatory eﬀect of anti-IgE antibodies. In contrast
Xiaetal.[109]didnotﬁndtheexpressionofanyIgEreceptor
on tissue-forming cells in tissue sections. This discrepancy
to other studies [98–103] may be explained by diﬀerent
methods or antibodies to detect IgE receptors. Further
studies have to reassess the tissue compartmental expression
of Ig receptors in the healthy and diseased lung.
Recently it was reported that human airway smooth
muscle cells also express the IgG receptors, FcγRs-I, and -IIb
[109]. Furthermore, the activation by IgG downregulated IL-
1α induced cytokine production and reduced the activation
of the two signaling proteins Erk1/2 MAPK and p38 MAPK.
In sharp contrast to other studies the authors did not ﬁnd
any expression of the IgE receptors in their isolated cells.
No reports are available for the expression of other im-
munoglobulin receptors on human airway smooth muscle
cells.Thepossiblefunctionoftheimmunoglobulinreceptors
on human airway smooth muscle cells is summarized in
Figure 3.
The above scarce data is evidence that the role of tissue-
forming resident cell activation by immunoglobulins, not
only IgE, must be investigated in more detail.
6. Conclusion
Tissue-forming cells of the human lung express and respond
to the activation of at least two immunoglobulin receptors,
IgG and IgE receptors. Thereby they directly contribute
directly to inhale environmental factor such as allergens or
dust without the need to activate immune reactive cells.
The mechanism(s) that induce and control the expression
of immunoglobulin receptor in these cell types have not
been studied extensively. The relevance of the in vitro data
on immunoglobulin receptor expression by tissue-forming
resident lung cells has to be conﬁrmed in vivo and its
relevance to the pathologies of chronic inﬂammatory lung
diseases has to be demonstrated. Ignoring the fact that these
cells are an active participant in the lung’s immune response
to inhaled environmental factors will only delay the search
for a better understanding of the distinct pathologies of
the diﬀerent chronic inﬂammatory lung diseases, and it will
delay the search for new therapeutic strategies.
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